- PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4 YL)AMINO]NICOTINIC ACID
-
The present disclosure relates to a process for manufacturing 2-[(3,5-difluoro-3′-methoxy-1,1′biphenyl-4-yl)amino]nicotinic acid.
- -
-
Page/Page column 6
(2012/10/08)
-
- Amino derivatives for the treatment of proliferative skin disorders
-
Compositions comprising specific amino derivatives for their use in treating proliferative skin diseases or disorders and the use of specific amino derivatives in such a treatment is disclosed
- -
-
-
- PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID
-
This invention is directed to a process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1' biphenyl-4-yl)amino]nicotinic acid, which comprises the steps of: a) providing 3,5-difluoro-3'-methoxybiphenyl-4-amine, b) preparing and isolating an aminium salt of the 3,5-difluoro-3'-methoxybiphenyl- 4-amine, and c) further reacting the aminium salt of 3,5-difluoro-3'-methoxybiphenyl-4-amine obtained in b) to obtain 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4- yl)amino]nicotinic acid.
- -
-
Page/Page column 15
(2011/05/05)
-
- Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
-
This invention is directed to a process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid, which comprises the steps of: a) providing 3,5-difluoro-3'-methoxybiphenyl-4-amine, b) preparing and isolating an aminium salt of the 3,5-difluoro-3'-methoxybiphenyl-4-amine, and c) further reacting the aminium salt of 3,5-difluoro-3'-methoxybiphenyl-4-amine obtained in b) to obtain 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid.
- -
-
Page/Page column 8
(2011/05/05)
-
- AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS
-
A compound of formula (I) wherein : - one of the groups G1represents a nitrogen atom or a group CRc and the other represents a group CRc; - G2 represents a nitrogen atom or a group CRd; - R1 represents a group selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - R2 represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - Ra, Rb and Rc independently represent groups selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - Rd represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C3-8 cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - one of the groups G3 and G4 is a nitrogen atom and the other is a CH group; - M is a hydrogen atom or an pharmaceutically acceptable cation with the proviso that, when at least one of the groups Ra and Rb represent a hydrogen atom and G2 is a group CRd, then Rd represents a groups selected from C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C3-8 cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; and the pharmaceutically acceptable salts and N-oxides thereof.
- -
-
Page/Page column 38
(2008/12/06)
-